Is zanidatamab better than trastuzumab in HER2 IHC 2+?

Thoughts on the HER2 3+ and HER2 2+/ISH+ subgroups for zanidatamab, and its mechanism of action JACOB trial: https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(18)30481-9/abstract INNOVATION trial: https://ascopubs.org/doi/10.1200/JCO.2025.43.4_suppl.LBA331 HERIZON-GEA-01: https://www.nejm.org/doi/full/10.1056/NEJMoa2517729 Zanidatamab preclinical study: https://pmc.ncbi.nlm.nih.gov/articles/PMC10011572/N